MS Pharma Partners With Mabxience For Bevacizumab In MENA Region
Follows Agreement With Alvion For Rosuvastatin/Ezetimibe In MENA
Executive Summary
Jordan-based MS Pharma has struck a deal with Insud Pharma subsidiary Mabxience to commercialize its bevacizumab biosimilar in the Middle East and North Africa region. The move comes after Mabxience partnered with Zentiva to commercialize bevacizumab in 21 European countries. Meanwhile, MS Pharma has also partnered with Alvion Pharma for rosuvastatin/ezetimibe in the MENA region.
You may also be interested in...
Apotex Begins Roll Out Of Avastin Biosimilar In Canada
Following recent Health Canada approval, Apotex has launched partner mAbxience’s Bambevi (bevacizumab) biosimilar across Canada, adding to its portfolio of biosimilars that includes both filgrastim and pegfilgrastim.
Deal Watch: Lilly Teams Up With Lycia In Protein Degradation
Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.
Stada Launches Bevacizumab Biosimilar In EU
Stada has launched its Oyavas version of bevacizumab upon EU approval, initially rolling out the oncology biosimilar in Germany and the Netherlands with other countries to follow.